日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Author Correction: Targeting the SHOC2-RAS interaction in RAS-mutant cancers

作者更正:靶向 RAS 突变癌症中的 SHOC2-RAS 相互作用

Hauseman, Zachary J; Stauffer, Frédéric; Beyer, Kim S; Mollé, Sandra; Cavicchioli, Elena; Marchand, Jean-Remy; Fodor, Michelle; Viscomi, Jessica; Dhembi, Anxhela; Katz, Stéphanie; Faggion, Beatrice; Lanter, Mylene; Kerr, Grainne; Schildknecht, Daniela; Handl, Cornelia; Maddalo, Danilo; Pissot Soldermann, Carole; Brady, Jacob; Shrestha, Om; Nguyen, Zachary; Leder, Lukas; Cremosnik, Gregor; Lopez Romero, Sandra; Hassiepen, Ulrich; Stams, Travis; Linder, Markus; Galli, Giorgio G; Guthy, Daniel A; King, Daniel A; Maira, Sauveur-Michel; Thoma, Claudio R; Ehmke, Veronika; Tordella, Luca

Targeting the SHOC2-RAS interaction in RAS-mutant cancers.

靶向 RAS 突变癌症中的 SHOC2-RAS 相互作用

Hauseman Zachary J, Stauffer Frédéric, Beyer Kim S, Mollé Sandra, Cavicchioli Elena, Marchand Jean-Remy, Fodor Michelle, Viscomi Jessica, Dhembi Anxhela, Katz Stéphanie, Faggion Beatrice, Lanter Mylene, Kerr Grainne, Schildknecht Daniela, Handl Cornelia, Maddalo Danilo, Pissot Soldermann Carole, Brady Jacob, Shrestha Om, Nguyen Zachary, Leder Lukas, Cremosnik Gregor, Lopez Romero Sandra, Hassiepen Ulrich, Stams Travis, Linder Markus, Galli Giorgio G, Guthy Daniel A, King Daniel A, Maira Sauveur-Michel, Thoma Claudio R, Ehmke Veronika, Tordella Luca

Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

作者更正:基于 DCAF1 的 PROTAC 具有针对临床验证靶点的活性,可克服内在和获得性降解剂耐药性。

Schröder, Martin; Renatus, Martin; Liang, Xiaoyou; Meili, Fabian; Zoller, Thomas; Ferrand, Sandrine; Gauter, Francois; Li, Xiaoyan; Sigoillot, Frederic; Gleim, Scott; Stachyra, Therese-Marie; Thomas, Jason R; Begue, Damien; Khoshouei, Maryam; Lefeuvre, Peggy; Andraos-Rey, Rita; Chung, BoYee; Ma, Renate; Pinch, Benika; Hofmann, Andreas; Schirle, Markus; Schmiedeberg, Niko; Imbach, Patricia; Gorses, Delphine; Calkins, Keith; Bauer-Probst, Beatrice; Maschlej, Magdalena; Niederst, Matt; Maher, Rob; Henault, Martin; Alford, John; Ahrne, Erik; Tordella, Luca; Hollingworth, Greg; Thomä, Nicolas H; Vulpetti, Anna; Radimerski, Thomas; Holzer, Philipp; Carbonneau, Seth; Thoma, Claudio R

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

BRD9降解剂作为急性白血病和多发性骨髓瘤的化疗增敏剂

Weisberg, Ellen; Chowdhury, Basudev; Meng, Chengcheng; Case, Abigail E; Ni, Wei; Garg, Swati; Sattler, Martin; Azab, Abdel Kareem; Sun, Jennifer; Muz, Barbara; Sanchez, Dana; Toure, Anthia; Stone, Richard M; Galinsky, Ilene; Winer, Eric; Gleim, Scott; Gkountela, Sofia; Kedves, Alexia; Harrington, Edmund; Abrams, Tinya; Zoller, Thomas; Vaupel, Andrea; Manley, Paul; Faller, Michael; Chung, BoYee; Chen, Xin; Busenhart, Philipp; Stephan, Christine; Calkins, Keith; Bonenfant, Debora; Thoma, Claudio R; Forrester, William; Griffin, James D

Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability

定量图像分析表明 pVHL 是微管动态不稳定性的一个关键调控因子。

Thoma, Claudio R; Matov, Alexandre; Gutbrodt, Katrin L; Hoerner, Christian R; Smole, Zlatko; Krek, Wilhelm; Danuser, Gaudenz

Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3

糖原合成酶激酶3对肿瘤抑制因子pVHL的启动依赖性磷酸化和调控

Hergovich, Alexander; Lisztwan, Joanna; Thoma, Claudio R; Wirbelauer, Christiane; Barry, Robert E; Krek, Wilhelm